Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance

dc.creatorSantos, Théo Araújo
dc.creatorAndrade, Bruno de Bezerril
dc.creatorSantana, Leonardo Gil
dc.creatorLuz, Nívea Farias
dc.creatorSantos, Priscila Lima dos
dc.creatorOliveira, Fabrícia A. de
dc.creatorAlmeida, Meirielly Lima
dc.creatorCampos, Roseane Nunes de Santana
dc.creatorBozza, Patrícia Torres
dc.creatorAlmeida, Roque Pacheco de
dc.creatorBorges, Valeria de Matos
dc.date2017-07-10T18:37:39Z
dc.date2017-07-10T18:37:39Z
dc.date2017
dc.date.accessioned2023-09-26T22:41:33Z
dc.date.available2023-09-26T22:41:33Z
dc.identifierSANTOS, T. A. et al. Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance. Scientific Reports, v. 7, n.1, p. 4334, 2017.
dc.identifier2045-2322
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/20030
dc.identifier10.1038/s41598-017-04595-8
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8882005
dc.descriptionFundação de Amparo à Pesquisa do Estado da Bahia-FAPESB (RED0018/2013 to V.M.B.) and from Conselho Nacional de Desenvolvimento Científico e Tecnológico-CNPq (478480/2013-0 to V.M.B., 552721/2011-5 and 019.203.02712/2009-8 FAPITEC/CNPq to R.P.A.). R.P.A. also received a grant from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES: 23038.005304/2011-01).
dc.descriptionVisceral leishmaniasis (VL) remains a major public health problem worldwide. Cytokine balance is thought to play a critical role in the development of this disease. Here, we perform a prospective exploratory study addressing whether simultaneous assessment of circulating levels of different lipid mediators and cytokines could highlight specific pathways involved with VL pathogenesis. VL patients displayed substantial increases in serum levels of Prostaglandin F2α (PGF2α), Leukotriene B4 (LTB4), Resolvin D1 (RvD1), IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α compared with uninfected endemic control group, while exhibiting decreased levels of TGF-β1. Hierarchical cluster analysis of the prospective changes in the expression level of theses parameters upon anti-Leishmania treatment initiation revealed that the inflammatory profile observed in active disease gradually changed over time and was generally reversed at day 30 of therapy. Furthermore, not only the individual concentrations of most of the inflammatory biomarkers changed upon treatment, but the correlations between those and several biochemical parameters used to characterize VL disease activity were also modified over time. These results demonstrate that an inflammatory imbalance hallmarks active VL disease and open perspective for manipulation of these pathways in future studies examining a potential host-directed therapy against VL.
dc.formatapplication/pdf
dc.languageeng
dc.publisherNature Publishing Group
dc.rightsopen access
dc.subjectLeishmaniose visceral
dc.subjectBiomarcadores
dc.subjectSaúde pública
dc.subjectTratamento
dc.subjectInflamação
dc.subjectVisceral leishmaniasis
dc.subjectBiomarkers
dc.subjectPublic health
dc.subjectTreatment
dc.subjectInflammation
dc.titleAnti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
dc.typeArticle


Este ítem pertenece a la siguiente institución